Accueil
Détail de l'auteur
Documents disponibles écrits par cet auteur
Ajouter le résultat dans votre panier Faire une suggestion Affiner la rechercheArticle : Périodique
Background and Aims: Fatal outcome of opioid overdose, once detected, is preventable through timely administration of the antidote naloxone. Take-home naloxone provision directly to opioid users for emergency use has been implemented recently in[...]Article : Périodique
J. STRANG ; R. McDONALD ; B. TAS ; E. DAY |Context: Take-home naloxone is increasingly provided to prevent heroin overdose deaths. Naloxone 0.4-2.0 mg is licensed for use by injection. Some clinicians supply improvised nasal naloxone kits (outside lisenced approval). Is this acceptable? [...]Article : Périodique
J. STRANG ; R. McDONALD ; A. ALQURSHI ; P. ROYALL ; D. TAYLOR ; B. FORBES |Introduction: Deaths from opioid overdose can be prevented through administration of the antagonist naloxone, which has been licensed for injection since the 1970s. To support wider availability of naloxone in community settings, novel non-injec[...]Rapport
OEDT = EMCDDA ; J. STRANG ; R. McDONALD ; D. HEDRICH ; R. SIMON | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2016This publication examines the case for distributing naloxone, an emergency medication, to people who inject opioids such as heroin and to others who might witness an opioid overdose. Through its capacity to reverse opioid overdose, naloxone can [...]Article : Périodique
Background: Opioid overdose is a major cause of mortality, but injury and fatal outcomes can be prevented by timely administration of the opioid antagonist naloxone. Pre-provision of naloxone to opioid users and family members (take-home naloxon[...]
